Abstract
Metabolic disorders such as obesity, type 2 diabetes, and dyslipidaemia are major drivers of cardiovascular risk and have reached epidemic levels in Western populations. Recent advances in clinical research have uncovered unexpected and often beneficial effects of pharmacological classes of metabolic drugs on cardiovascular outcomes, revealing complex interactions between metabolism and cardiac pathology. Despite their clinical efficacy, the molecular and cellular mechanisms through which many of these agents act remain only partially understood. This gap in knowledge underscores the urgent need for fundamental research that not only dissects the biology of metabolic disorders and cardiovascular disease but also reveals the mechanistic basis of existing and emerging therapies, thereby enabling rational therapeutic development. This scientific statement, developed by researchers from the European Society of Cardiology (ESC) Council on Basic Cardiovascular Science and several ESC Working Groups, provides a state-of-the-art overview of the emerging molecular and cellular pathways linking metabolic abnormalities with vascular and cardiac disease. By illuminating these critical connections and unresolved questions, this article aims to catalyse innovation in the prevention and management of cardiovascular disease in the context of metabolic dysfunction and to suggest new directions for future research.
| Original language | English |
|---|---|
| Number of pages | 18 |
| Journal | European Heart Journal |
| Early online date | 6 Mar 2026 |
| DOIs | |
| Publication status | E-pub ahead of print - 6 Mar 2026 |
Data Availability Statement
No data were generated or analysed for or in support of this paper.Funding
P.C.E. is supported by the British Heart Foundation (RG/19/10/34506). G.V. is supported by a Grant PID2021-128891OB-I00 and PLEC2021–007664- NextGenerationEU funded by MCIN/AEI/10.13039/501100011033 and Fondo Europeo de Desarrollo Regional (FEDER) A way of making Europe. This article is based upon work from COST Action, CA22169 EU-METAHEART (GV, PK) supported by COST (European Cooperation in Science and Technology). E.O. is supported by the Swiss National Science Foundation PRIMA: PR00P3_179861/1 and the Swiss Life Foundation, the Heubergstiftung, the Philhuman Stiftung, Novartis Foundation and the Swiss Heart Foundation (FF 19111}, Switzerland. R.M. is supported by the Italian Ministry of University and Research under PNRR - M4C2-I1.3 Project PE_00000019 ‘HEAL ITALIA’, PRIN 2022 Prot. 2022S74XWB and PNRR-NRR-MR1-2022-12376879} S.D. is supported by the British Heart Foundation (PG/21/10798), UK. C.A.R. is supported by the Netherlands CardioVascular Research Initiative (CVON-PREDICT2 2018-30) and the European Joint Research Program on Rare Diseases (EJP-RD; Joint Transnational Call 2020). E.L. is supported by the LeDucq Foundation (CHECKPOINT ATHERO consortium, 22CVD02). W.A.L. is supported by the German Research Foundation (Li 690/14-1). D.D. is supported by the British Heart Foundation (PG/24/11930, FS/CRTF/23/24508, FS/CRTF/22/24275, BHF PG/22/11117, FS/RTF/20/30009, NH/19/1/34595), the National Institute for Health and Care Research Health Technology Assessment (NIHR157523), and Tenovus Scotland (G23.03, G24.07). L.B. is supported by grants from the Fonds National de la Recherche Scientifique (FNRS, Belgium). C.P. is supported by Italian Ministry of Health (PNRR- MR1-2022-12376858), Italian Ministry of University and Research (2020YRETTX_003) and grant CN00000041 ‘National Center for Gene Therapy and Drugs based on RNA Technology’ (concession number 1035 of 17 June 2022-PNRR MUR - M4C2 - Investment 1.4 Call ‘National Centers’, financed by EU- NextGenerationEU, project code (CUP) E63C22000940007).
| Funders | Funder number |
|---|---|
| British Heart Foundation | RG/19/10/34506, PG/21/10798, PG/24/11930, FS/CRTF/23/24508, FS/CRTF/22/24275, BHF PG/22/11117, FS/RTF/20/30009, NH/19/1/34595 |
| National Institute for Health and Care Research | NIHR157523 |
| Tenovus Scotland | G23.03, G24.07 |
| European Regional Development Fund | PID2021-128891OB-I00, PLEC2021–007664- NextGenerationEU |
| Ministerio de Ciencia e Innovación | |
| Agencia Estatal de Investigación | |
| European Cooperation in Science and Technology | CA22169 EU-METAHEART |
| Swiss National Science Foundation | PRIMA: PR00P3_179861/1 |
| Swiss Heart Foundation | FF 19111 |
| Ministero dell'università e della ricerca | PE_00000019, PRIN 2022 Prot. 2022S74XWB, PNRR-NRR-MR1-2022-12376879 |
| Netherlands CardioVascular Research Initiative | CVON-PREDICT2 2018-30 |
| European Joint Research Program on Rare Diseases | |
| Leducq Foundation | 22CVD02 |
| German Research Foundation | Li 690/14-1 |
| Fonds National de la Recherche Scientifique | |
| Ministero della Salute | PNRR- MR1-2022-12376858 |
| Ministero dell'università e della ricerca | 2020YRETTX_003, CN00000041 |
| NextGenerationEU | E63C22000940007 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Obesity
- Metabolic disorders
- Metabolism
- Incretin-based therapies
- Cardiovascular disease
Fingerprint
Dive into the research topics of 'Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities: A scientific statement of the ESC Council on Basic Cardiovascular Science, the ESC Working Group on Atherosclerosis and Vascular Biology, the ESC Working Group on Cellular Biology of the Heart, the ESC Working Group on Myocardial Function, and the ESC Working Group on Cardiac Cellular Electrophysiology'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS